Utilizing Risk Index for Overdose Or Serious Opioid-Induced Respiratory Depression (Riosord) Scores to Prioritize Offer of Rescue Naloxone in An Outpatient Veteran Population: A Telephone-Based Project

Abstract

Background

Since 2014, the Department of Veterans Affairs (VA) has been working to address the ongoing opioid epidemic through opioid-education initiatives, the development of risk calculators, and other risk stratification tools. One primary focus of VA efforts has been the distribution of rescue naloxone kits to veterans at greatest risk of opioid-related adverse events. The purpose of this project was to identify primary care veterans at highest risk for serious opioid-related adverse events using the Risk Index for Overdose and Serious Opioid-Induced Respiratory Depression (RIOSORD) and offer rescue naloxone kits by telephone-based outreach. RIOSORD is a risk-stratification tool developed and validated within the veteran population.

Methods

Veterans identified at highest risk of overdose or opioid-related adverse effects were contacted by telephone or letter to offer to provide a rescue naloxone kit between November 1^st, 2016 and February 1^st, 2017. The primary outcome of the project was the percentage of patients contacted that agreed to a naloxone prescription. Secondary outcomes included comparative efficacy of phone versus letter contact and reasons for refusal of naloxone if the offer was declined.

Results

Of 41 veterans targeted by this project, most were successfully reached by telephone within three attempts (92.7%, n = 38). Approximately two-thirds of those reached by telephone agreed to a prescription for rescue naloxone (n = 26, 63.4%). The veterans that requested rescue naloxone selected the nasal formulation (n = 17) over the intramuscular auto-injector (n = 9).

Conclusions

This project demonstrated that telephone-based outreach can be one method of distributing rescue naloxone to a high-risk patient population without requiring an in-person visit to a provider.

Keywords

Analgesics–opioid;drug overdose naloxone Veterans respiratory insufficiency telephone

Get full access to this article

View all access options for this article.

References

U.S. Department of Health and Human Services (HHS), Office of the surgeon general, facing addiction in america: The surgeon general's report on alcohol, drugs, and health. Washington, DC: HHS; November 2016.

Binswanger

, Koester

, Mueller

, Gardner

, Goddard

, Glanz

. Overdose education and naloxone for patients prescribed opioids in primary care: A qualitative study of primary care Staff. J Gen Intern Med. 2015;30(12):1837–44.

Zedler

, Xie

, Wang

, . Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in veterans’ health administration patients. Pain Med. 2015;16(8):1566–79.

Krieter

, Chiang

, Gyaw

, Skolnick

, Crystal

, Keegan

, Aker

, Beck

, Harris

(2016). Pharmacokinetic properties and human use characteristics of an fda-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 56:1243–1253. doi:10.1002/jcph.759

Edwards

, Edwards

, Davis

, Mulcare

, Wiklund

, Kelley

. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther. 2015;4(1):89–105.

Substance Abuse and Mental Health Services Administration. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. The DAWN Report. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2013. Available from URL: http://www.samhsa.gov/data/2k13/DAWN127/sr127-DAWN-highlights.htm

Centers for Disease Control and Prevention. Increases in drug and opioid overdose deaths — united states, 2000–2014. MMWR. 2015;64;1–5.

Narcan [package insert]. Radnor, PA: Adapt Pharma, Inc.; 2015.

Evzio [package insert]. Richmond, VA: Kaleo, Inc.; 2014.